Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NFX88 (2-OHOA) for neuropathic pain in spinal cord injury: randomized phase 2 trial
2018-004792-13Phase 2Completed
- Sponsor
- Neurofix Pharma
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of 2-hydroxyoleic acid in Neuralgia, spinal cord injury (SCI), sponsored by Neurofix Pharma. Started Apr 2019; status: completed.
02
Drugs
2-hydroxyoleic acid
03
Conditions
Neuralgiaspinal cord injury (SCI)
Beyond the preview
Go deeper on 2018-004792-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004792-13.